TWO) on Monday reported a loss of $79.1 million in its first quarter. The St. Louis Park, Minnesota-based company said it had a loss of 89 cents per share. Earnings, adjusted for non-recurring costs, ...

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...